2024
N-Methyl-d-Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia
Tong J, Yang K, Li W, Wang L, Yin Y, Zhou Y, Huang J, Zhang P, Zhao Y, Chen S, Fan H, Cui Y, Luo X, Tan S, Wang Z, Feng W, Tian B, Li C, Hong L, Tan Y. N-Methyl-d-Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia. Schizophrenia Bulletin 2024, sbae180. PMID: 39406395, DOI: 10.1093/schbul/sbae180.Peer-Reviewed Original ResearchFirst-episode schizophreniaSensory gating deficitsN-methyl-D-aspartate receptorsFirst-episode schizophrenia groupGating deficitsN-methyl-D-aspartateP50 ratioSensory gatingExposure to antipsychotic medicationAb levelsHealthy controlsAntipsychotic medication exposureFirst-episode patientsDiagnosis of schizophreniaImpaired sensory gatingP50 sensory gating deficitN-methyl-D-aspartate receptor antibodiesAntipsychotic medicationFirst-episodeNon-smoking healthy controlsP50 differenceSchizophreniaPartial correlation analysisEnzyme-linked immunosorbent assayDeficitsProgressive alterations of resting-state hypothalamic dysconnectivity in schizophrenia
Li X, Zeng J, Liu N, Yang C, Tao B, Sun H, Gong Q, Zhang W, Li C, Lui S. Progressive alterations of resting-state hypothalamic dysconnectivity in schizophrenia. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2024, 135: 111127. PMID: 39181307, DOI: 10.1016/j.pnpbp.2024.111127.Peer-Reviewed Original ResearchHypothalamic functional connectivityBilateral anterior cingulate cortexAnterior cingulate cortexFunctional connectivityFES patientsCingulate cortexFC decreaseRight thalamusChronically treated schizophrenia patientsHealthy controlsSeed-based functional connectivityFirst-episode patientsPathogenesis of schizophreniaNature of schizophreniaAge-related declineAntipsychotic treatmentAntipsychotic medicationRight caudateLeft putamenIllness durationAnalysis of covarianceSchizophreniaDiagnostic groupsHC groupHypothalamus dysfunctionSerum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders
Li Y, Wang L, Huang J, Zhang P, Zhou Y, Tong J, Chen W, Gou M, Tian B, Li W, Luo X, Tian L, Hong L, Li C, Tan Y. Serum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders. Frontiers In Psychiatry 2024, 15: 1357293. PMID: 38680780, PMCID: PMC11046465, DOI: 10.3389/fpsyt.2024.1357293.Peer-Reviewed Original ResearchYoung Mania Rating ScaleBD-DAffective disordersBD-MDepressive symptomsHamilton Depression Scale-17 itemsRemission of depressive symptomsKynurenic acidMania Rating ScaleAcute manic episodeWeeks of antidepressantsRisk of MDDKynurenine pathwayAssociated with remissionAntipsychotic medicationDisrupt tryptophan metabolismManic symptomsDepressive disorderBD-D.Depressive episodeHAMD-17Mood stabilizersManic episodesBipolar disorderTryptophan pathway
2020
Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★
Huang J, Zhu Y, Fan F, Chen S, Hong Y, Cui Y, Luo X, Tan S, Wang Z, Shang L, Yuan Y, Zhang J, Yang F, Li CR, Rowland LM, Kochunov P, Zhang F, Hong LE, Tan Y. Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★. Psychiatry Research Neuroimaging 2020, 297: 111043. PMID: 32062167, PMCID: PMC7490244, DOI: 10.1016/j.pscychresns.2020.111043.Peer-Reviewed Original ResearchTreatment-resistant schizophreniaTreatment-responsive patientsHippocampal volumeHealthy controlsSmaller total hippocampal volumesSmaller hippocampal volumesTotal hippocampal volumeAvailable antipsychotic medicationsSevere cognitive dysfunctionLogistic regression analysisSubgroup of schizophreniaGlobal cognitive deficitsCognitive domain deficitsSpecific deficitsAntipsychotic medicationCognitive dysfunctionTreatment resistanceHigh riskHC groupPatientsMemory deficitsCognitive deficitsCognitive functionSchizophreniaSignificant deficits